Can You Sue Depo-Provera for Meningioma? Alarming Pfizer Lawsuit & 3,769 Victims 2026

If you used Depo-Provera and were diagnosed with a meningioma brain tumor, the answer to the critical question — can you sue Depo-Provera for meningioma? — is yes. As of May 2026, more than 3,769 plaintiffs have already filed Depo-Provera meningioma lawsuits against Pfizer in MDL 3140, making this one of the most active pharmaceutical mass tort cases in the U.S. federal court system. The Depo-Provera meningioma lawsuit 2026 represents a legal reckoning for Pfizer’s failure to warn patients about the alarming meningioma risks of its injectable birth control. Call 1 (855) 664-8713 now for a free, confidential case evaluation — no upfront cost, no fee unless you win.

My name is Mason Arnao, and my background in data systems, technology infrastructure, and digital advocacy has given me a deep understanding of how the Depo-Provera meningioma lawsuit 2026 affects real people navigating complex legal and medical systems. As publisher of TortAdvisor.com and President of Waypoint Software — a leading digital firm with over 20 years of experience — I’ve built systems that connect people with critical information. In this guide, I’ll explain exactly who can sue, what the legal basis is, how to file, and what your case may be worth.

The Legal Basis: Can You Sue Depo-Provera for Meningioma?

Yes — you can sue Depo-Provera (Pfizer) for meningioma under multiple legal theories recognized across all U.S. states. The primary legal claims in the Depo-Provera meningioma lawsuit 2026 are failure to warn, design defect, and negligence. Failure to warn is the strongest and most widely pursued claim: Pfizer had a legal duty to inform patients and prescribing physicians of the meningioma risk associated with long-term MPA use — a risk supported by scientific evidence for years before the FDA required a label update. The FDA’s decision to mandate a meningioma warning is itself powerful evidence that the risk was real and the failure to warn was actionable. Notably, you don’t need to prove Depo-Provera was the only cause — only that it was a substantial contributing factor to your meningioma, a lower and more achievable legal standard for victims.

Additionally, negligence claims cover Pfizer’s failure to conduct adequate post-market surveillance, failure to update safety communications proactively, and failure to advise prescribers to screen long-term Depo-Provera patients. Moreover, some plaintiffs allege design defect — that MPA’s formulation and dosing created unreasonably elevated meningioma risk compared to alternative contraceptive options. The convergence of failure to warn, negligence, and design defect claims across thousands of cases is what makes MDL 3140 so significant. Visit our complete Depo-Provera lawsuit guide for a detailed breakdown of the legal claims and their evidentiary basis.

The Science: Why Pfizer Is Being Sued for Depo-Provera Meningioma

The scientific evidence supporting the Depo-Provera meningioma lawsuit is robust and growing. A landmark 2024 study in the British Medical Journal — analyzing over 18,000 meningioma cases — found dramatically elevated risk among women using high-potency progestins including medroxyprogesterone acetate (Depo-Provera). Risk increased with duration: women using Depo-Provera for 3+ years showed the highest risk elevations. The biological mechanism is well-established: meningioma cells express progesterone receptors in 60–80% of cases, according to NIH research, making them directly stimulated by synthetic MPA. Furthermore, clinical evidence documents meningioma regression after Depo-Provera discontinuation — one of the strongest proofs of causation. The FDA acknowledged this evidence by requiring a meningioma warning on Depo-Provera’s label, directly supporting the failure-to-warn claims at the core of MDL 3140.

Importantly, the meningioma risk from Depo-Provera was not unknown in the scientific community — similar risks from other high-potency progestins had been documented in European research and regulatory actions years before U.S. litigation was filed. Plaintiffs argue that Pfizer had constructive knowledge of meningioma risk through this established body of progestin research and failed to act on it. This is a key element establishing Pfizer’s liability across all Depo-Provera meningioma claims. Additionally, the American Cancer Society data on meningioma incidence — approximately 34,000 new U.S. diagnoses annually, with women affected at twice the rate of men — aligns precisely with the demographic most affected by Depo-Provera use.

Who Can Sue Depo-Provera for Meningioma?

The right to sue Depo-Provera for meningioma belongs to anyone who meets the core eligibility criteria in MDL 3140. You likely qualify if: you received Depo-Provera injections for 12+ consecutive months; you were diagnosed with a meningioma (any grade) confirmed by MRI, CT, or pathology; your Depo-Provera use preceded your diagnosis; and you are within your state’s statute of limitations (typically 2–3 years from diagnosis or discovery). Surviving family members may also sue Depo-Provera for wrongful death if a loved one used the drug and their meningioma was a contributing factor in their death — often yielding higher compensation. Furthermore, cases involving Grade II or Grade III malignant meningiomas, surgical resection, radiation therapy, or significant documented disability typically yield the highest settlement amounts. To confirm your eligibility, call 1 (855) 664-8713 or visit our Depo-Provera legal options page.

MDL 3140 Update: Where the Depo-Provera Lawsuits Stand in May 2026

MDL 3140 is actively progressing in the Northern District of Illinois as of May 2026, with more than 3,769 plaintiffs filed and new cases added weekly. The litigation has reached the Daubert hearing phase — the pivotal stage where expert scientific testimony on the Depo-Provera meningioma link is evaluated for admissibility. Favorable Daubert rulings for plaintiffs would accelerate the path to bellwether trials, which in turn typically trigger global settlement negotiations. Legal analysts project a global MDL settlement fund of $1.5 billion to $3+ billion, though individual case values will vary substantially based on injury severity. The JPML website provides official MDL 3140 docket updates. Time is critical: statutes of limitations are real, and the longer you wait, the greater the risk of losing your right to file.

Full Eligibility Checklist: Can You Sue Depo-Provera?

• Depo-Provera use ≥ 12 months: Received injectable MPA (Depo-Provera/medroxyprogesterone acetate) for 12 or more consecutive months at any time
• Meningioma diagnosis: Confirmed by MRI, CT, or surgical pathology — Grade I, II, or III all qualify
• Causal timeline: Depo-Provera use preceded the meningioma diagnosis
• Statute of limitations: Within 2–3 years of diagnosis date or discovery of the Depo-Provera connection (varies by state)
• U.S. resident: All U.S. states qualify — no geographic restriction
• No prior settlement: Have not previously settled this specific claim against Pfizer

Depo-Provera Meningioma Settlement Amounts 2026

Settlement amounts in the Depo-Provera meningioma lawsuit depend on meningioma grade, surgical and radiation treatment history, documented disability, age, and duration of Depo-Provera use. Use our free Depo-Provera settlement calculator for a personalized estimate. Estimated ranges from MDL projections and comparable case precedents:

To estimate your individual case value, use our Depo-Provera settlement calculator. You can also review comparable settlement data at our mass tort settlement amounts page. Our attorneys also handle hair relaxer cancer lawsuits, Ozempic lawsuits, and PFAS cancer lawsuits — all on a no-fee-unless-you-win basis.

How to File Your Depo-Provera Meningioma Lawsuit

Suing Depo-Provera is handled entirely by your attorney on a contingency fee basis. Here is the process step by step:

1. Free Evaluation: Call 1 (855) 664-8713 or submit your information online — 5 minutes to confirm eligibility.
2. Medical Records: Your legal team gathers Depo-Provera records and meningioma diagnosis documentation (MRI, surgical pathology).
3. Retain MDL Attorney: You sign a contingency fee agreement with an MDL 3140 specialist — zero upfront cost.
4. Complaint Filed: Your individual case is filed in MDL 3140, Northern District of Illinois. No court appearances needed.
5. Discovery and Resolution: MDL coordinated discovery, potential bellwether selection, and eventual settlement or verdict — estimated 2–4 year timeline.

Estimate Your Depo-Provera Settlement Amount

Use our free Depo-Provera settlement calculator before you call — it takes under two minutes and gives you an immediate personalized estimate of your case value.

Frequently Asked Questions: Can You Sue Depo-Provera for Meningioma?

About the Author

My name is Mason Arnao, and my background in data systems, technology infrastructure, and digital advocacy has given me a deep understanding of how the Depo-Provera meningioma lawsuit 2026 affects real people navigating complex legal and medical systems. As publisher of TortAdvisor.com and President of Waypoint Software — a leading digital firm with over 20 years of experience — I’ve built systems that connect people with critical information. In this guide, I’ve addressed the critical question of whether you can sue Depo-Provera for meningioma and provided everything you need to take action.